

Review Article

Cognitive Improvement through Persian Medicinal Plants: A Mechanistic Overview

Ghasem Khazen, Fereshteh Farajdokht, Saeed Sadigh-Eteghad, Ahad Banagozar Mohammadi, Fatemeh Ebrahimi, Javad Mahmoudi

DOI: 10.34172/PS.026.42835

To appear in: Pharmaceutical Science (<https://ps.tbzmed.ac.ir/>)

Received date: 30 Jun 2025

Revised date: 24 Nov 2025

Accepted date: 25 Nov 2025

Please cite this article as: Khazen G, Farajdokht F, Sadigh-Eteghad S, Banagozar Mohammadi A, Ebrahimi F, Mahmoudi J. Cognitive improvement through Persian medicinal plants: A mechanistic overview. Pharm Sci. 2026. doi: 10.34172/PS.026.42835

This is a PDF file of a manuscript that have been accepted for publication. It is assigned to an issue after technical editing, formatting for publication and author proofing.

Cognitive Improvement through Persian Medicinal Plants: A Mechanistic Overview

Ghasem Khazen^{1,2}, Fereshteh Farajdokht¹, Saeed Sadigh-Eteghad¹, Ahad Banagozar Mohammadi², Fatemeh Ebrahimi^{3*}, Javad Mahmoudi^{1,4*}

¹ Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

² Department of Persian Medicine, Faculty of Persian Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

³ Department of Traditional Pharmacy, Faculty of Persian Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

⁴ Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

*Correspondence to:

Fatemeh Ebrahimi, Department of Traditional Pharmacy, Faculty of Persian Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. E-mail address: fthebrahimi@gmail.com, ebrahimif@tbzmed.ac.ir

Javad Mahmoudi, Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, & Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. E-mail address: mahmoudi2044@gmail.com

Ghasem Khazen: <https://orcid.org/0009-0003-6183-2492>

Fatemeh Ebrahimi: <https://orcid.org/0000-0002-8514-0656>

Javad Mahmoudi: <https://orcid.org/0000-0001-9755-9422>

Running title: Cognitive Improvement and Persian medicine

Conflict of Interests: The authors have no relevant financial or nonfinancial interests to disclose.

Author Contributions:

Conceptualization: **FE, JM**

Investigation: **GK, FE, JM, SS-E,**

Methodology: **GK, ABM**

Project administration: **FE, SS-E, FF**

Resources: **GK, FE**

Supervision: **FE, JM**

Validation: **FF, JM, ABM**

Visualization: **FE, JM**

Writing-Original Draft: **FE, GK, ABM**

Writing-review & editing: **FF, JM, FE**

Acknowledgements: This study was financially supported by a grant (No. 71160) from Tabriz University of Medical Sciences (Tabriz, Iran).

Abstract

Cognition relates to the mental processes engaged in acquiring knowledge and comprehension via thought, experience, and the senses. However, cognitive abilities can progressively decline with age over time or due to certain health conditions, affecting the overall quality of life. Neurodegenerative dementia is more likely to affect older adults because of aging. Despite the availability of various conventional therapeutic approaches, they often come with high costs or unwanted side effects. So, finding new interventions to improve cognitive performance remains a hot topic of research. Recently, there has been growing interest in using medicinal plants, as abundant and affordable phytochemical compound resources. This study introduces the most prevalent and accessible medicinal plants in Persian medicine for preventing and treating cognitive impairments. Also, the scientific evidence of the plant efficacy was searched in electronic databases with keywords including the scientific plant names and cognition or memory or Alzheimer's disease (AD) or amnesia or learning, by focusing on recent credible animal and clinical studies. Every relevant clinical study was thoroughly reviewed and included in this review. Findings suggest these natural remedies may alleviate dementia and cognitive decline through key mechanisms such as antioxidant activity, anti-inflammatory effects, anti-apoptotic properties, and enhancement of cholinergic transmission. Additionally, several plants inhibit amyloid- β and tau depositions while promoting neurotrophic signaling pathways. Although these medicinal plants could be promising candidates as future drugs or adjunct therapies, further research is necessary to confirm their safety and efficacy, as well as to understand their precise underlying mechanisms of action, potential interactions and appropriate therapeutic dosages.

Keywords: cognition disorders, medicinal plants, phytotherapy, Persian medicine.

Introduction

As the global population continues to age, the rate of cognitive impairments among the elderly is increasing.¹ Neurocognitive disorders affect different cognitive disciplines, including memory, attention, language, and executive functions.² These impairments are categorized into dementia and non-dementia. Dementia is the more severe form and encompasses various types: AD (characterized by progressive memory loss and cognitive decline), vascular dementia (cognitive decline due to vascular deficits), and frontotemporal dementia (affecting behavior, personality, and language).

Studies show that oxidative stress, neuroinflammation, and mitochondrial dysfunction stand as the main recognized molecular mechanisms for these disorders that result in neurodegeneration and synaptic loss seen in cognitive deficits.^{3,4} About 11.3% of individuals aged 65 and older have AD, the most prevalent dementia.⁵ According to predictions, the number of people with AD will be doubled by 2040 in developing countries.⁶ The disease not only reduces the life satisfaction of patients but also imposes a huge burden on society and the health care system. Due to the rapid growth in the prevalence of the disease and the challenges it poses for both patients and society, new treatment and prevention methods seem necessary.⁷

Different types of medicinal plants and their isolated compounds have been employed not only to boost cognitive function and memory but also to prevent related impairments.⁸ Traditional medicines serve as unique and invaluable sources of medicinal plants employed in the treatment of diverse health conditions. Plants such as *Ginkgo biloba* L. and *Panax ginseng* C.A.Mey. in Chinese medicine⁹, *Bacopa monniera* (L.) Pennell, *Asparagus racemosus* Willd and *Centella Asiatica* (L.) Urban in Ayurveda⁹, *Moringa oleifera* Lam. and *Mesembryanthemum tortuosum* L. in African traditional medicine¹⁰ are all known ancient herbal remedies used as nootropics and memory enhancers.

The literature of traditional Persian medicine (TPM) proposes various candidates for addressing cognitive and memory impairments such as AD.^{11,12} The neuroprotective plants, such as *Piper nigrum* and *Crocus sativus*, are examples that can reduce cognitive impairments in Alzheimer's disease, likely due to their antioxidant properties.¹¹

This review aims to shed light on the most common medicinal plants used in TPM for the prevention and attenuation of memory impairments. This study is distinguished from previous works by highlighting the prevalent features of these plants, including their potent pharmacological properties, wide accessibility, and affordability. In addition, it provides a comprehensive evaluation of all relevant clinical studies of these plants, ensuring that the scientific evidence supporting their efficacy in humans is fully captured.

Search strategy

In this review, herbal remedies mentioned in TPM textbooks were derived and used as the keywords for subsequent search. Therefore, the most important TPM medicinal books and pharmacopeias including *Ghanoon fel-teb* (The Canon of Medicine, written by Avicenna in 1025 AD), *Gharabadin kabir* (written by Aghili Alavi Khorasani in 1772 AD), *Makhzan Al-adviah* (the largest pharmacopeia of Persian medicine written by Aghili Alavi Khorasani in 1771 AD), and *Exir azam* (a comprehensive medical encyclopedia written by Azam Khan in 1868 AD) were explored to identify relevant prescriptions for enhancing memory, learning and attention as well as amnesia treatment. Ten commonly cited and accessible medicinal plants were selected based on our search strategy, and their scientific names were identified using authentic references. Subsequently, the evidence for their efficacies was searched in electronic databases (including PubMed, Scopus, and Google Scholar) using combination of plant names and the keywords 'cognitive*', 'cognition', 'amnesia', 'memory', 'learning', and 'AD'. Data were collected from 2000 to 2024. The analysis was restricted to English-language publications, with a primary focus on clinical studies. In addition, relevant *in-vitro* and *in-vivo* studies were reviewed to clarify pharmacological mechanisms. Clinical studies evaluating pharmaceutical products were excluded from the analysis. Major Pharmacopeias were also reviewed to provide documentation for the selected medicinal plants.

Results

The ten most frequently cited medicinal plants in TPM references and their associated details (including ethnobotanical information, main compound classes and ingredients, and pharmacologic effects) for the prevention and treatment of cognitive disorders are presented in Table 1. The captured images of medicinal plants are presented in Figure 1. Searching scientific

databases supported the anti-inflammatory, antioxidant and anti-AchE activity properties of these plants by *in-vitro*, animal and clinical studies. The comprehensive list of relevant clinical evidence on the pharmacologic effects of the plants is represented in Table 2. Each paragraph concerning related plants outlines the mechanisms underlying the efficacy of these plants in AD and cognitive disorders.

To demonstrate the significance of these selected plants, their coverage in the “WHO International Pharmacopoeia (Ph. Int.)”¹³ as well as in several prominent national pharmacopoeias, including the “British Pharmacopoeia (BP)”¹⁴, “United States Pharmacopoeia (USP)”¹⁵, “European Pharmacopoeia (EP)”¹⁶, “Ayurvedic Pharmacopoeia of India (API)”¹⁷, and the “Pharmacopoeia of the People’s Republic of China (ChP)”¹⁸ was evaluated. The summarized findings are presented in Table 3. The analysis revealed that all ten plants were found in at least one major pharmacopoeia. Species with dual culinary-medicinal use such as garlic, ginger, and saffron appeared across nearly all pharmacopoeias, while others including frankincense, cardamom, lavender, lemon balm, black seed, and Damask rose, were represented more selectively. The results illustrate how variations in global use and traditional medicinal practices affect pharmacopoeial coverage.

Table 1. Prominent pharmacological effects of selected medicinal plants in TPM for cognitive disorders.

| Scientific name | Family | Common name | Traditional name | Part used | Major phytochemical classes | Main active ingredients | Pharmacologic Effect | References |
|--------------------------|----------------|------------------------|------------------|---------------|-----------------------------|---|--|------------|
| <i>Allium sativum</i> L. | Amaryllidaceae | Garlic | Soum | Rizhorme | Organosulfur compounds | Allicin, S-allyl cysteine, di-allyl disulfide | Anti-AchE, anti-oxidant, anti-AD, anti-neuroinflammation | 19-21 |
| <i>Boswellia</i> spp. | Burseraceae | Frankincense, olibanum | Kondor | Oleogum-resin | Triterpenoids | Incensole acetate, Boswellic acid, | Anti- AchE, anti- AD, anti-oxidant | 22-24 |

| | | | | | | | | |
|---|---------------|------------------------|---------------|-------------|------------------------------------|---|---|----------|
| <i>Crocus sativus</i> L. | Iridaceae | Saffron | Zafaran | Stigma | Carotenoids, Monoterpenoids | Crocin, crocetin, safranal | Anti- Alzheimer, anti-oxidant | 25-27 |
| <i>Elettaria cardamomum</i> (L.) Maton | Zingiberaceae | Green cardamom | Hel | Fruit | Monoterpenoids | 1,8-cineole, α -Terpinyl acetate | Anti-inflammatory, Anti-oxidant, anti- AD | 28-30 |
| <i>Lavandula angustifolia</i> Mill. | Lamiaceae | True lavender | Ostokhodus | Aerial part | Monoterpenoids, phenolic compounds | linalool, rosmarinic acid, caffeic Acid, luteolin | Anti- AD, antioxidant, anti-AchE | 31-34 |
| <i>Melissa officinalis</i> L. | Lamiaceae | Lemon balm | Badranjbouyeh | Aerial part | Monoterpenoids, phenolic acids | Citral, rosmarinic acid | antioxidant, anti-AchE, anti-AD | 27,35,36 |
| <i>Nigella sativa</i> L. | Ranunculaceae | Black cumin | Sian daneh | Seed | Quinones, phenolic compounds | Thymoquinone, carvacrol | Anti-inflammatory, antioxidant, anti- AchE, anti- AD | 37-39 |
| <i>Piper nigrum</i> L. | Piperaceae | Black pepper | Felfel e siah | Seed | Alkaloids, lignans | Piperine, sesamin | Neuroprotective, Antioxidant, Anti- AchE, anti-AD | 40-42 |
| <i>Rosa damascena</i> Mill. | Rosaceae | Iranian or Damask rose | Gol e sorkh | flower | Monoterpenoids | Citronellol, geraniol, nerol | Neuroprotective, Antioxidant, Anti- AchE, anti-AD, anti-inflammatory | 43-45 |
| <i>Zingiber officinale</i> Rosc. | Zingiberaceae | Ginger | Zanjebil | Rhizome | Phenolic ketones | 6-shogaol, 6-gingerol | Anti-inflammatory, anti-apoptosis, neuroprotective, anti- AD, and Antioxidant | 46,47 |

AchE: Acetylcholinesterase, AD: Alzheimer's disease.

***Allium Sativum* L. (Amaryllidaceae)**

A. Sativum L., known as garlic, is one of the most common herbs used both as flavor and herbal medicine since ancient times. Garlic is widely cultivated around the world, with major production regions including East and South Asia, South Asia, and parts of Europe and North America.²⁰ It is one of the memory enhancing herbs used in TPM. Allicin (diallyl thiosulfinate) is the major organosulfur compound found in garlic, which is activated when garlic is crushed or chopped.²¹ It is proposed that organosulfur derivatives of *A. Sativum* L., including allicin, diallyl disulfide, and diallyl trisulfide which all exert anti-oxidant and anti-apoptosis activity as well as anti-gliosis properties contribute to its neuroprotective and pro-cognitive effects.²¹ The aged form of garlic, a processed product rich in stable organosulfurs such as S-allylcysteine and diallyl-disulfide, has been shown in vivo to exhibit potent antioxidant and anti-inflammatory effects. These compounds also modulate neurotransmitters, including cholinergic, glutamatergic, and GABAergic pathways. This evidence suggests that aged garlic may be an effective candidate for preventing cognitive decline in AD.^{48,49}

It has been shown that *A. sativum* powder could alleviate monosodium glutamate-induced neurotoxicity by improvement of short-term memory dysfunction, oxidative stress burden, and gliosis in rats.¹⁹ Interestingly, in the smoker rat model of inflammation, the ethanol extract of garlic significantly reduced pro-inflammatory cytokine levels, highlighting its potential for suppressing inflammatory reactions linked to molecular changes in the brain of AD patients.²⁰ Moreover, findings showed that taking 400 mg of encapsulated garlic powder led to significant improvements in visual memory tests and the rapid visual Information Processing (RVP) test for attention in healthy volunteers compared to the placebo group, indicating its ability to enhance higher levels cognitive abilities.⁵⁰ According to different studies, Allicin and S-allylcysteine compounds could inhibit A β Aggregation via direct interaction with A β peptides, suggesting garlic's Potential in preventing and treating age-related A β accumulation such as in AD.^{51,52}

***Boswellia* Spp. (Burseraceae)**

Frankincense oleo-gum-resin, which is obtained from trees of genus *Boswellia*, is called Kondor in TPM. *Boswellia* spp. are native to Northeast Africa, the Arabian Peninsula, India, and parts of Sudan.⁵³ Avicenna, proposed that Kondor resin could improve memory function and prevent

amnesia in elderly.⁵⁴ Several clinical studies have shown the effectiveness of formulations containing this resin on cognitive impairment experienced by AD patients.⁵⁵⁻⁵⁷ Evidence from rat model of AD demonstrated that *B. serrata* methanolic extract could not only significantly inhibits the neuroinflammatory procedures via normalization of machineries including C-reactive protein, nuclear factor kappa B, monocyte chemotactic protein-1, and leukotriene B4 levels, but also restored cerebral acetylcholine content to normal levels and eliminated amyloid- β plaques in the hippocampus samples.⁵⁸ Moreover, it has been shown that chronic administration of *B. serrata* gum in type 2 diabetic rats, which mimic the learning and memory impairments seen in AD, improved cognitive abnormalities partly via modulation of glutamate receptors, increasing acetylcholine content and anti-oxidant enzymes activities, suppression of oxidative stress, inflammatory cytokines, and Glycogen synthase kinase-3 beta (GSK-3 β) as well as reduction of p-tau and amyloid- β accumulation in the hippocampus.⁵³ Additionally, findings indicated that incensole acetate, one of the major derivatives of Boswellia resin, restores hippocampal-related learning and memory deficits in lipopolysaccharide-treated rats. This improvement is primarily resulted through the increase in hippocampal brain-derived neurotrophic factor (BDNF) levels and the inhibition of gliosis, which in turn leads to elevated levels of pro-inflammatory cytokines, nitric oxide, and oxidative stress markers.⁵⁹ Moreover, findings indicated that boswellic acid, an active compound derived from *B. serrata*, effectively improves antioxidant abilities and mitigates mitochondrial dysfunction in a rat model of AD. In the boswellic acid-treated AD group, there was a significant decrease in hippocampal levels of glucose, L-malondialdehyde, tau protein, and glutathione peroxidase. Additionally, boswellic acid exerts potential therapeutic effects in management of both AD and type 2 diabetes, emphasizing its relevance in metabolic and neurodegenerative disorders.^{60,61}

***Crocus sativus* L. (Iridaceae)**

C. sativus L. commonly known as Saffron, is widely cultivated in Iran and countries such as India and Greece. The floral stigma of saffron is a precious spice and a potent ancient medicine used for treatment of conditions including depression and memory impairments.^{62,63}

In various studies, saffron and its phytoconstituents (mainly crocin, crocetin, and safranal) have been shown to exhibit significant neuroprotective effects through their antioxidant and anti-

inflammatory properties.⁶⁴ Additionally, saffron extracts not only inhibited the aggregation of A β plaques and tau protein tangles but also suppressed the acetylcholinesterase (AChE) activity.⁶⁵⁻⁶⁷ Collectively due to involvement of these procedures in AD pathophysiology, it seems that saffron may help to control the symptoms of AD.

In animal models of cognitive dysfunction, saffron administration has improved performance in memory-related tasks, suggesting its potential as a pro-cognitive compound. Moreover, studies indicate that crocin counteracts memory impairments induced by neurotoxic agents such as ethanol and aluminum chloride, possibly in part by enhancing long-term potentiation and promoting synaptic plasticity in the hippocampus, a critical region for learning and memory.^{68,69} Interestingly, crocin has been shown to increase the expression of BDNF and cAMP response element-binding protein (CREB). Both of which are crucial for synaptic plasticity and memory consolidation.⁷⁰

Safranal, the compound responsible for the aroma of saffron, indirectly improves cognitive functions via exhibiting anxiolytic effects and improving impairments in learning and memory. It seems that its regulatory effects on mood and cognitive processes originates from its influence on catecholamines, including dopamine and serotonin.^{71,72} Crocetin, a water-soluble pigment in saffron, has been shown to enhance mitochondrial function and reduce inflammation, which contributes to its protective effect against cognitive decline. In a rat model of vascular dementia, administration of crocetin has improved spatial learning and memory by decreasing escape latency in the Morris water maze and protecting cerebrocortical and hippocampal neurons from ischemic damage.⁷³ The cognitive-enhancing effects of *C. sativus* and its active components which are supported by clinical studies are presented in table.2.

***Elettaria cardamomum* (L.) Maton (Zingiberaceae)**

E. cardamomum, with the common name cardamom, is among the most popular spices. It is predominantly produced in India, Sri Lanka, and Nepal, with Guatemala serving as the largest global producer and exporter. In Traditional Persian Medicine (TPM), cardamom is recognized for its impact on the central nervous system.⁷⁴ The mechanisms underlying these effects are primarily attributed to its antioxidant, anti-inflammatory, and neuroprotective properties, which are mediated by various phytochemical constituents present in the plant.

In rat models of cerebral hypoperfusion, the essential oil of *E. cardamomum*, notably its component 1,8-cineole, exhibited anti-neurodegenerative effects by reducing pro-inflammatory cytokines such as Interleukin-1 beta (IL-1 β), tumor necrosis factor alpha (TNF- α), and inhibiting apoptosis.²⁸ Other animal models exhibited the nootropic effect of the ethanol extract possibly due to its antioxidant properties, anti-cholinesterase activity, and ability to lower glucose levels.²⁹ The neuroprotective activity and central cholinergic system modulation makes cardamom the potential adjunct in the management of cognitive decline in AD.⁷⁵ Although direct clinical evidences is still limited, inflammatory pathways modulation by cardamom affirms its benefits in AD.⁷⁶

***Lavandula angustifolia* Mill. (Lamiaceae)**

L. angustifolia (lavender) is a famous medicinal plant native to the Mediterranean basin and was historically cultivated in regions such as Turkey, the Levant, Iran, Afghanistan, and parts of the United Kingdom. In TPM, it is known as the great cleanser of the nervous system.^{11,77} A substantial body of evidence indicate that lavender extracts and essential, primarily containing linalool, rosmarinic acid, caffeic Acid and luteolin, enhance memory function and reduce AD related cognitive impairments, largely mediated by their antioxidant properties.^{32,78} In one study, the spatial performance of AD rats in Morris water maze task was normalized following treating with lavender aqueous extract. Findings revealed that while AD rats initially struggled to locate a hidden platform, administration of lavender extract, particularly at 200 mg/kg, resulted in significant improvement in their spatial learning and memory performance compared to the control group.³⁴

It seems that Lavender's pro-cognitive effects originate from its potential to reduce beta-amyloid production, as well as its antioxidant, anti-inflammatory, anti-apoptotic properties, and anti-acetylcholinesterase activity.^{31,79} This is consistent with research by Li et al³³ which demonstrated that lavender extracts show neuroprotective properties against accelerated dementia caused by D-galactose and aluminum trichloride in a zebrafish model, showing their capability as a treatment for AD. The study introduced linalool, a key bioactive compound in lavender, as a potential contributor to mitigating cognitive decline.³³

***Melissa officinalis* L. (Lamiaceae)**

M. officinalis, commonly known as lemon balm, is a medicinal plant belonging to the Lamiaceae family. It is native to the Mediterranean and Western Asia and is now widely cultivated in Europe, North America, and parts of Asia. Lemon balm is traditionally used for its diverse therapeutic properties, particularly for neurological and gastrointestinal effects.^{11,77} The evidences showed that *M. officinalis* extract, which is high in phenolics and flavonoids, considerably improved cognitive performance in rat models. As experimental study showed, *M. officinalis* exerted free radical scavenging effects which makes it as a suitable candidate for treatment of cognitive dysfunction.^{35,80} Furthermore, the ability of lemon balm for protection of neural cell from oxidative stress induced apoptotic death, have been established both in *in-vivo* and *in-vitro* models. Apparently, this effect is mediated in part via decreasing malondialdehyde levels and cysteine-aspartic proteases-3 (caspase-3) activity.^{36,81} In healthy individuals acute administration of lemon balm extract has been associated with enhanced mood and cognitive function.^{82,83} Moreover, results of a randomized controlled trial revealed that chronic administration of *M. officinalis* extract in patients with mild to moderate AD resulted in significant improvement in their cognitive abilities.⁸⁴

***Nigella sativa* L. (Ranunculaceae)**

N. sativa, often known as black cumin, is a well-known medicinal plant and spice. It is native to Southwest Asia, northern Africa, and the Mediterranean region and is now widely cultivated in countries such as India, Pakistan, Egypt, and parts of the Middle East. In TPM, it used for its neurological and general health-promoting effects. The seeds contain bioactive compounds such as thymoquinone and beta-caryophyllene, which are believed to improve learning and memory.^{85,86} A study on the effect of oral black seed oil on motor skill learning in mice, using a single pellet reaching task, revealed its beneficial impact on improving learning outcomes. The observed effect may be attributed to thymoquinone and carvacrol, which are potent antioxidants and have ability to increase synaptic strength and boost experience-dependent motor skill learning.³⁹ As animal studies suggested, thymoquinone's neuroprotective effect in improving the cognitive functions may be mediated by the anti-oxidant activity and inhibitory effects on degeneration of pyramidal cells in the hippocampus.^{37,38} Confirming prior reports, daily administration of 500 mg *N. sativa* capsules, once daily for 4 weeks in healthy young

volunteers and twice daily for 9 weeks in healthy older adults, improved emotional and cognitive outcomes in both groups.^{87,88} These findings support *N. sativa* as a preferred herb for daily use.

***Piper nigrum* L. (Piperaceae)**

Black pepper is a valuable medicinal plant and spice, native to southern India and now widely cultivated throughout tropical regions worldwide.⁸⁹ *P. nigrum* is regarded as one of the most effective enhancers of memory and mental performance.⁹⁰ Piperine, the main bioactive ingredient in black pepper, has been identified as an essential element for neuroprotective and cognitive-enhancing properties. A result of animal study showed that cold-pressed oil from black pepper fruits, (rich in sesamin and piperine), improved cognitive performance in scopolamine induced rat model of dementia. On the basis of in silico molecular docking and histopathological investigations, it considerably enhanced the rat cognitive behaviors as compared to the donepezil received group, modified the activity of antioxidant enzymes such as catalase, while reducing the levels of malondialdehyde and hippocampus acetylcholinesterase.⁴⁰ According to evidence from animal studies, *P. nigrum* is able to decrease AchE levels and amyloid plaque, emphasizing on its effectiveness for management of memory loss in AD.^{41,42} Limited clinical studies represented the efficacy of mixed herbal therapies containing *p. nigrum* in the improvement of memory in mild-to-moderate AD patients and enhancement of sustained attention and motivation to do cognitive works in low energy young adults.^{91,92} For instance, a double-blind, randomized clinical trial by Tajadini et al. evaluated the efficacy of a traditional herbal compound containing *Piper nigrum*, *Cyperus rotundus*, *Zingiber officinale*, *Acorus calamus*, and *Boswellia carterii*, in mild-to-moderate AD patients. After 12 weeks, the intervention group demonstrated significantly greater improvements in cognitive function compared to the placebo group.⁹¹

***Rosa damascena* Mill. (Rosaceae)**

R. damascena, an appealing perennial shrub, is renowned for its aromatic and flavoring properties. It is extensively cultivated in Iran, especially in Kashan region and also grows in temperate regions across the world including Turkey, Bulgaria, and parts of Europe and the

Middle East.⁹³ In TPM, Iranian rose is recognized as a brain tonic that supports cognitive function.⁹⁴ The antioxidant and anti-inflammatory effects of the plant, which underlie its neurological benefits, are primarily attributed to its monoterpene alcohols, particularly citronellol, geraniol, and nerol.⁹⁵ In aluminum chloride induced rat model of AD, administration of aqueous extract of *R. damascena* not only resulted in the regulation of AChE activity and increase in anti-oxidant elements (glutathione and catalase) but also reduced cerebral lipid peroxidation levels, supporting its potential for treatment of AD complications.⁴⁴ In another study, administration of *R. damascena* essential oil in scopolamine received rats improved learning and memory and augmented Ach neurotransmission, increased the expression of M1 Muscarinic acetylcholine receptors, and brain-derived neurotrophic factor in cerebral tissues. The possible molecular interactions between the human M1 Muscarinic acetylcholine receptors and the main components of *R. damascena* oil, mainly citronellol, geraniol, and nerol, have been further clarified by computational modelling, indicating the potential of damask rose oil on memory impairments in neurodegenerative disorders.⁴³ Furthermore, it has been shown that *R. damascena* extract exhibits neuroprotective properties, including the reduction of neuroinflammation and A β toxicity in animal models. These findings position it as a promising candidate for a therapeutic development in AD.^{45,96}

***Zingiber officinale* Roscoe. (Zingiberaceae)**

Ginger is regarded as a valuable herb not just for its role as a spice in culinary, but also for its historical use in traditional medicine. *Z. officinale* is widely cultivated in tropical and subtropical regions, including Northeast India, China, Sudan, and Taiwan.⁹⁷ It is believed to be effective in improving memory and combating the effects of aging in TPM. Ginger is a rich source of bioactive compounds, with 6-shogaol and 6-gingerol being the key constituents responsible for its health benefits.⁴⁷

One of the primary mechanisms by which *Z. officinale* exerts its cognitive benefits is through AChE inhibitory effects. Studies have shown that ginger extracts, containing active compounds like 6-gingerol and 6-shogaol, significantly inhibit AChE which leads to improvement of memory performance in various animal models of cognitive disorders.^{46,98,99} In an animal study, the 6-gingerol-rich fraction alleviated Acrylonitrile -induced brain injury in male rats by normalizing

malondialdehyde, interleukin-6, tumor necrosis factor- α , and Nitric Oxide levels as well as preserving glutathione and superoxide dismutase function. Moreover, the extract decreased cerebral cortical lesions caused by Acrylonitrile and enhanced the expression of Caspases-9 and -3, indicating its potential to prevent neuronal apoptosis induced by Acrylonitrile.¹⁰⁰ Overall, many *in-vitro* and *in-vivo* evidences supported that ginger's biological agents have the potential to alleviate neurological symptoms and diseases, probably via influencing brain ' monoamine and cholinergic neurotransmissions, exerting anti-oxidant activity, reducing inflammation.⁴⁷ The underlying neuroprotective mechanisms through which the above mentioned medicinal plants improve cognitive impairments are illustrated in Figure 2.

Table 2. List of clinical studies on the pharmacological effects of the plants in populations with neurodegenerative, psychiatric, cardiovascular, and metabolic disorders, as well as in healthy or cognitively intact individuals.

| Plant | Intervention | | Study design | Patients | Treatment duration | Results | References (year) |
|---|--|------------------------------|---|--|--------------------|--|--------------------------|
| | Treatment group | Control group | | | | | |
| <i>Boswellia sacra</i> Flueck. | Herbal capsule, 500 mg (TID) containing <i>B. sacra</i> resin, <i>M. officinalis</i> , <i>Piper longum</i> , <i>Cinnamomum verum</i> , and <i>Physalis alkekengi</i> | Maltodextrin, 500 mg (TID) | Double-blinded, placebo-controlled trial | 60 patients With mild-to-moderate AD or mild cognitive impairment | 3 months | Herbal capsule was significantly more effective than placebo in improving cognitive and behavioral symptoms | ¹⁰¹ (2022) |
| <i>Boswellia papyrifera</i> (Delile ex Caill.) Hochst. | <i>B. papyrifera</i> capsule, 300 mg (BID) | Placebo capsule 300 mg (BID) | Randomized, double-blinded, placebo-controlled clinical trial | 80 patients with relapsing-remitting multiple sclerosis | 2 months | Herbal capsule significantly improved visual-spatial memory, no significant effect on verbal memory (CVLT) or information processing speed | ¹⁰² (2014) |
| <i>Boswellia serrata</i> Roxb. | Herbal tablet, 27 mg (BID), containing <i>B. serrata</i> and <i>M. officinalis</i> extract | Placebo capsule (BID) | Randomized, parallel, double-blinded, placebo-controlled | 70 older adults with No history of psychological disorder or AD | 1 month | significant increase in the total memory score of the intervention group was observed | ⁵⁶ (2017) |

| | | | clinical trial | | | | | |
|--|--|--|---|---|-----------|--|---------------|--|
| Allium sativum L. | A. sativum capsule, 400 mg (BID) | Placebo capsule, 400 mg (BID) | Randomized controlled trial | 20 healthy volunteers | 5 weeks | Improvement in Visual Memory test, significant increase in attention measures, Nonsignificant Effects on Verbal Memory | 50 (2015) | |
| Crocus sativus L. | Crocin, 15 mg (BID) | Placebo, 15 mg (BID) | Randomized clinical trial | 60 opioid patients undergoing methadone maintenance treatment | 12 weeks | Craving and withdrawal symptoms significantly reduced, Nonsignificant effect on cognitive function | 103 (2021) | |
| | Saffron capsule, 15 mg (BID) | Placebo capsule (BID) | Randomized, double-blinded, placebo-controlled clinical trial | 76 patients undergoing coronary artery bypass grafting (CABG) | 12 weeks | Nonsignificant effect on (CABG)-related Cognition, Anxiety, and Depression | 104 (2018) | |
| | Saffron (not mentioned the form of medication) | No treatments received | Single-Blind Randomized, with Parallel Groups, Clinical Trial | 35 patients with amnesic and multi domain mild cognitive impairment | 12 months | beneficial effect on cognitive function by improvement of Mini-Mental State Examination (MMSE) scores | 105 (2016) | |
| | Saffron capsule, 15 mg (BID) | Placebo capsule, 15 mg (BID) | Randomized placebo-controlled trial | 46 patients with mild to moderate AD | 16 weeks | Significant improvement of cognitive function in treatment group was observed | 106 (2010) | |
| | Saffron capsule, 15 mg (BID) | Donepezil, 5 mg (BID) | Randomized, double-blinded, controlled clinical trial | 54 patients with mild to moderate AD | 22 weeks | Saffron effects were similar to donepezil in the treatment of mild-to-moderate AD | 26 (2010) | |
| Elettaria cardamomum (L.) Maton | Herbal capsule, 44 mg (BID) containing Cardamom, Bacopa monnieri, Gotu kola leaf, Turmeric whole | Placebo capsule, standard-use magnesium stearate (BID) | Randomized, placebo-controlled trial | 128 cognitively intact older adults | 3 months | Increased speed of cognitive task performance, negative effects on memory | 107 (2023) | |

powder, Reishi full spectrum, Rosemary, Holy Basil, Turmeric extract, Green Tea, Seagreens

***Lavandula angustifolia* Mill.**

| | | | | | | |
|--|---|---|---|---------------|---|---------------|
| 2 groups: one group lavender aromatherapy and another group rosemary aromatherapy (three days in the week) | Water in diffuser (three days in the week) | Randomized, placebo-controlled trial | 144 healthy volunteers | Not mentioned | No distinct effect of lavender group on cognitive performance, positive effects on mood | 108 (2003) |
| Aromatherapy of rosemary and lemon essential oils in the morning, and lavender and orange in the evening | No placebo | Interventional crossover trial | 28 elderly people, 17 with AD, 3 with vascular dementia, and 8 with other diagnoses | 28 days | significant improvement of all patients specially AD patients in personal orientation related to cognitive function | 109 (2009) |
| 3 groups: aromatherapy of 3 individual essential oils: lavender, Rosemary, and Orange (30min/day, 3 days/week) | Placebo | Parallel randomized controlled clinical trial | 86 patients under chronic hemodialysis | 1 month | For lavender group: no significant change in prospective memory problems and decrease in retrospective memory problems, No difference between 3 groups | 110 (2022) |
| 2 groups: One group lavender aromatherapy and another group rosemary aromatherapy | Placebo | prospective, randomized trial | 63 elderly people with diabetes | 4 weeks | Lavender improved cognitive functions and sleep quality and reduced anxiety | 111 (2024) |
| Aromatherapy with lavender essential oil 10min (BID) | Aromatherapy with distilled water 10min (BID) | Randomized clinical trial | 60 women with multiple sclerosis | 2 weeks | statistically significant enhancement in working memory | 112 (2021) |

| | | | | | | | |
|-------------------------------|--|-------------------------------|---|---|---------------------------------------|--|---------------|
| | Aromatherapy with lavender essential oil before procedure | No placebo | Clinical trial | 20 healthy adults | once | significant changes in oscillatory power and behavioral performance | 113 (2024) |
| | Aromatherapy of rosemary-lemon oil in the mornings for one week, followed by lavender oil in the evenings for another week | No placebo | pretest-posttest clinical trial | 39 older adults | 2 weeks | Lavender oil reduced daytime sleepiness and improved cognitive function | 114 (2022) |
| Melissa officinalis L. | <i>M. officinalis</i> extract supplementation, 500 mg, once per day | Placebo, 500 mg, once per day | Randomized placebo-controlled double-blind trial | 232 patients with subjective or mild cognitive impairment | 96 weeks | <i>M. officinalis</i> extract may help prevent cognitive decline in older adults without hypertension | 115 (2023) |
| | <i>M. officinalis</i> extract supplementation, 500 mg, once per day | Placebo, 500 mg, once per day | Randomized placebo-controlled double-blind trial | 23 patients with mild dementia due to probable AD | 24 weeks | <i>M. officinalis</i> extract may help prevent the worsening of AD-related neuropsychiatric symptoms | 116 (2020) |
| | <i>M. officinalis</i> powder capsules with 7 days interval, Single doses of 600, 1000, and 1600 mg | Placebo, Single dose | Randomized placebo-controlled double-blind trial | 20 healthy, young participants | Testin g on the same day of treatment | 1600 mg doses can improve cognitive performance and mood | 117 (2003) |
| | <i>M. officinalis</i> extract, 60 drops/day | Placebo, 60 drops/day | Randomized placebo-controlled double-blind trial | 42 patients with mild to moderate AD | 4 months | Significant improvement in cognitive function, reduction of agitation | 84 (2003) |
| | <i>M. officinalis</i> extract capsules with 7 days interval, Single doses of 300, 600 and 900 mg | Placebo, Single dose | Randomized placebo-controlled double-blind balanced-crossover | 20 healthy, young participants | Testin g on the same day of treatment | improvement in mood and accuracy of attention with dose 600 mg, reductions in both Secondary memory and working memory factors | 83 (2002) |

| | | | | | | | | | |
|------------------------------------|---|--|---|--|--------|----------------------|--|------------|--|
| | | | trial | | | | | | |
| | Mixed extract of <i>M. officinalis</i> L., <i>Salvia officinalis</i> L., <i>Rosmarinus officinalis</i> L., 50 ml/day | <i>Myrrhis odorata</i> extract with non-cognitive effects, 50 ml/day | Randomized double-blind placebo-controlled pilot trial | 44 healthy subjects | normal | 2 weeks | Improvement of verbal episodic memory | 118 (2018) | |
| <i>Nigella sativa</i> L. | <i>N. sativa</i> capsule, 500 mg, once daily | placebo capsule, 500 mg, once daily | Randomized placebo-controlled double-blind trial | 48 healthy adolescent human males | | 4 weeks | Mood stabilization, decrease in anxiety and cognition improvement | 88 (2014) | |
| | <i>N. sativa</i> capsule, 500 mg (BID) | Placebo capsule, 500 mg (BID) | Randomized placebo-controlled double-blind trial | 40 healthy elderly | | 9 weeks | Significant enhancement in memory, attention and cognition | 87 (2013) | |
| <i>Piper nigrum</i> L. | <i>P. nigrum</i> capsule, 500 mg, in three mixed herbal orders: <i>P. nigrum</i> then placebo, Rosemary then <i>P. nigrum</i> , Rosemary then placebo | Rice flour capsule, 500 mg | Double-blind, randomized, placebo-controlled crossover experiment | 40 young adults with lower feeling of energy | | Testing after 2 days | Significant short-term enhancement of sustained attention, motivation to do cognitive work | 92 (2013) | |
| | Herbal capsule, 500 mg (TID), containing: <i>P. nigrum</i> , <i>Cyperus rotundus</i> , <i>Zingiber officinale</i> , <i>Acorus calamus</i> , and <i>Boswellia carterii</i> , | Placebo capsule, 500 mg (TID) | Randomized double-blind placebo-controlled clinical trial | 44 older patients with mild to moderate AD | | 12 weeks | improvement of memory in patients with mild-to-moderate AD | 91 (2015) | |
| <i>Rosa damascena</i> Mill. | Donepezil and <i>R. damascena</i> extract capsules | Placebo and <i>R. damascena</i> capsules | Randomized double-blind, placebo-controlled clinical trial | 40 elderly patients with dementia | | 3 months | Improved cognitive impairment, depression and behavioral problems | 96 (2018) | |

Zingiber officinale Rosc. Ginger extract capsule, once daily, 2 groups of 400 mg and 800 mg Placebo capsule, once daily Randomized double-blind, placebo-controlled clinical trial 60 healthy, middle-aged women 2 months enhanced memory and cognitive functions working cognitive 119 (2012)

mg: milligrams, TID: three times a day, AD: Alzheimer's disease, BID: twice a day.

Table 3. Presence of selected medicinal plants across major pharmacopeias.

| Plant Name | Ph. Int. | BP | USP | EP | API | ChP. |
|--|----------|----|-----|----|-----|------|
| <i>Allium sativum</i> L. | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ |
| <i>Boswellia</i> spp. | ☑ | – | – | – | ☑ | – |
| <i>Crocus sativus</i> L. | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ |
| <i>Elettaria cardamomum</i> (L.) Maton | ☑ | – | – | – | ☑ | – |
| <i>Lavandula angustifolia</i> Mill. | ☑ | ☑ | – | ☑ | – | – |
| <i>Melissa officinalis</i> L. | ☑ | ☑ | – | ☑ | – | – |
| <i>Nigella sativa</i> L. | ☑ | – | – | – | ☑ | – |
| <i>Piper nigrum</i> L. | ☑ | ☑ | ☑ | ☑ | ☑ | – |
| <i>Rosa damascena</i> Mill. | – | ☑ | ☑ | – | – | – |
| <i>Zingiber officinale</i> Rosc. | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ |

☑: means the presence, –: means the absence, Ph. Int.: WHO International Pharmacopoeia, BP: British Pharmacopoeia, USP: United States Pharmacopoeia, EP: European Pharmacopoeia, API: Ayurvedic Pharmacopoeia of India, ChP: Pharmacopoeia of the People's Republic of China.

Discussion

This review demonstrated the effectiveness of selected medicinal plants in alleviating cognitive dysfunction and memory impairments. The primary mechanisms involved were antioxidant and anti-inflammatory properties that restore redox balance, inhibit microglial activation, and reduce pro-inflammatory mediators such as TNF- α , IL-1 β , and nuclear factor kappa B (NF- κ B).¹²⁰ Many of these plants also enhance cholinergic neurotransmission via inhibition of AchE and increasing Ach levels in synaptic clefts. In addition, they are not only able to stabilize mitochondrial membrane potential, but also inhibit apoptosis partly by suppression of caspase-3 activity, which collectively results in neuronal cell vitality. The majority of these medicinal plants can also reduce amyloid- β deposition and tau hyper-phosphorylation by regulating enzymes like

GSK-3 β . Besides, the augmentation of the BDNF/CREB signaling pathway was another contributing mechanism, improving synaptic plasticity and neurogenesis.^{53,70} Moreover, modulation of the gut-brain axis may represent an emergent and crucial therapeutic mechanism. Medicinal plants could generate absorbable molecules through gut microbial metabolism, potentially enhancing cognitive function by rebalancing dysbiotic gut microbiota and lowering neuroinflammatory markers.¹²¹ Altogether, these mechanisms emphasize the multi-target, synergistic neuroprotective nature of these plants in the management of cognitive decline.

The focus on selecting these plants based on their safety and accessibility clarifies why many of them are dietary spices (e.g., garlic, saffron, and cardamom) or are available as infusion teas or standardized extracts (e.g., lavender, lemon balm, ginger, and black seed). While numerous preclinical experiments have been conducted on the listed plants, only a limited number of high-quality clinical studies exist. Limitations such as insufficient robust clinical trials, lack of standardized formulations, herb-drug interactions, and study heterogeneity make it difficult to fully validate their efficacy and long-term safety. Therefore, on the basis of the clinical evidence, the selected TPM plants are able to exert positive cognitive effects in AD, mild cognitive impairment, and dementia, with *Boswellia sacra*, *Crocus sativus*, *Melissa officinalis*, *Piper nigrum*, and *Rosa damascena* improving memory, behavior, and overall cognitive function. Benefits were also observed in healthy populations as well as individuals with neurological (multiple sclerosis, opioid treatment) and metabolic disorders, where *Lavandula angustifolia*, *Allium sativum*, *Elettaria cardamomum*, *Melissa officinalis*, *Nigella sativa*, and *Zingiber officinale* enhanced memory, attention, mood, and working memory, supporting their potential as cognitive enhancers across diverse populations.

Innovative drug delivery methods, such as intranasal administration and topical oil applications used in TPM for neurological disorders, show significant potential to bypass the blood–brain barrier and improve therapeutic efficacy. The effective medicinal plants documented in this review, along with TPM’s novel drug delivery systems, provide a strong foundation for developing safe, affordable, and non-toxic therapeutic agents in the form of medications,

dietary supplements, and integrative remedies for managing cognitive disorders. Importantly, these advancements not only pave the way for new therapies in cognitive health but also introduce and share Iran's rich cultural and traditional medicinal heritage with the world.

Conclusion and Future directions

Because cognitive impairment and dementia related to aging are becoming more common around the world, and because current drugs for AD are not very effective and may be associated with complications, there is a need for novel, safer, more affordable treatments.

Medicinal plants represent a promising link between TPM and current evidence-based medicine, offering accessible and cost-effective options for both preventive and adjunctive approaches to neurodegenerative disorders. Although there is promising preclinical evidence favoring their neuroprotective effects, many research gaps remain.

This includes the lack of standardized formulations and dosages, a poor understanding of pharmacokinetic and pharmacodynamic properties, and not enough translational research that links experimental findings to clinical outcomes. Furthermore, most recent researches are limited in scope, varied in methodology, and often lack comprehensive long-term follow-up data.

To address these limitations, future studies need to emphasize large-scale, multi-center, and rigorously designed randomized clinical trials to produce reliable evidence of efficacy and safety. Furthermore, efforts should concentrate on the standardization and quality assurance of bioactive components, mechanistic validation by advanced molecular and imaging techniques, and comprehensive assessments of long-term safety and any herb-drug interactions. These approaches will make the scientific basis of TPM-based medicines more reliable and facilitate their integration into standard healthcare systems.

References

1. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. *Lancet Neurol.* 2014;13(8):788-94. doi: 10.1016/S1474-4422(14)70136-X
2. Bai W, Chen P, Cai H, Zhang Q, Su Z, Cheung T, et al. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. *Age Ageing.* 2022;51(8):afac173. doi: 10.1093/ageing/afac173
3. Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. *Nat Neurosci.* 2018;21(10):1300-9. doi: 10.1038/s41593-018-0237-7
4. Namvaran Abbas-Abad A, Seyfizadeh N, Farzipour M, Pasokh A, Salatin S, Yazdanfar N. Amyloid beta and mitochondrial perturbations: an update on mechanisms and methods. *Biomed Res. Bull.* 2024;2(1):18-28. doi: 10.34172/biomedrb.2024.04
5. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. *Drugs Aging.* 1999;15:365-75. doi: 10.2165/00002512-199915050-00004
6. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World alzheimer report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends: Alzheimer's Disease International; 2015.
7. Safiri S, Noori M, Nejadghaderi SA, Mousavi SE, Sullman MJ, Araj-Khodaei M, et al. The burden of Alzheimer's disease and other types of dementia in the Middle East and North Africa region, 1990–2019. *Age Ageing.* 2023;52(3):afad042. doi: 10.1093/ageing/afad042
8. Kim H-G, Oh M-S. Herbal medicines for the prevention and treatment of Alzheimer's disease. *Curr Pharm Des.* 2012;18(1):57-75. doi: 10.2174/138161212798919002
9. Howes M-J R, Houghton P J. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. *Pharmacol Biochem Behav.* 2003;75(3):513-27. doi: 10.1016/S0091-3057(03)00128-X
10. Enogieru AB, Momodu OI. African medicinal plants useful for cognition and memory: therapeutic implications for Alzheimer's disease. *Bot Rev.* 2021;87:107-34. doi: 10.1007/s12229-021-09246-2
11. Shojaii A, Ghods R, Abdollahi Fard M. Medicinal herbs in Iranian traditional medicine for learning and memory. *Afr J Tradit Complement Altern Med.* 2016;13(2):199-209. doi: 10.21010/ajtcam.v13i2.24
12. Ebrahimi F, Torbati M, Khoshbakht Z, Khodaie L. Application of herbal rectal suppositories beyond intestinal disorders in Persian medicine. *Tradit. Med. Res.* 2019;4(3):160. doi: 10.12032/TMR20190414115
13. World Health Organization. *The International Pharmacopoeia*, 12th edition. Geneva: World Health Organization; 2025.
14. British Pharmacopoeia Commission. *British Pharmacopoeia 2025*. London: Medicines and Healthcare products Regulatory Agency (MHRA); 2025.
15. United States Pharmacopoeial Convention. *United States Pharmacopoeia and National Formulary (USP–NF)*. Rockville: United States Pharmacopoeial Convention; 2025.
16. Council of Europe. *European Pharmacopoeia*, 11th edition. Strasbourg: Council of Europe; 2025.
17. Government of India, Ministry of Health and Family Welfare, Department of AYUSH. *The Ayurvedic Pharmacopoeia of India*. New Delhi: Controller of Publications; 1989 (Volume I), with subsequent volumes published in different years.
18. Chinese Pharmacopoeia Commission. *Pharmacopoeia of the People's Republic of China*, 2020 Edition. 11th ed. Beijing: China Medical Science Press; 2020.
19. Hazzaa SM, Abdelaziz SAM, Abd Eldaim MA, Abdel-Daim MM, Elgarawany GE. Neuroprotective potential of *Allium sativum* against monosodium glutamate-induced excitotoxicity: impact on short-term memory, gliosis, and oxidative stress. *Nutrients.* 2020;12(4):1028. doi: 10.3390/nu12041028

20. Savira M, Sari DK, Machrina Y, Widjaja SS, Unityl AJA, Ilyas S, et al. Anti-inflammatory action of *Allium sativum* ethanol extract to prevent lung damage in smoker rat model. *Med Arch.* 2023;77(3):178-82. doi: 10.5455/medarh.2023.77.178-182
21. Nadeem MS, Kazmi I, Ullah I, Muhammad K, Anwar F. Allicin, an antioxidant and neuroprotective agent, ameliorates cognitive impairment. *Antioxidants (Basel).* 2021;11(1):87. doi: 10.3390/antiox11010087
22. Yousefsani BS, Barreto GE, Sahebkar A. Beneficial medicinal plants for memory and cognitive functions based on traditional Persian medicine. In: Barreto GE, Sahebkar A, editors. *Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health.* Cham: Springer; 2021. p. 283–90. doi: 10.1007/978-3-030-64872-5_20
23. Jamshidi AH, Eghbalian F, Mahroozade S, Mohammadi Kenari H, Ghobadi A, Yousefsani BS. Recommended natural products in Alzheimer's disease based on traditional Persian medicine. *J Med Plants.* 2020;19(75):17-29. doi: 10.29252/jmp.19.75.17
24. Hosseinzadeh H, Ramezani M, Akhtar Y, Ziaei T. Effects of *Boswellia carterii* gum resin fractions on intact memory and hyoscine-induced learning impairments in rats performing the Morris water maze task. *J Med Plants.* 2010;9(34):95-101.
25. Saleem S, Ahmad M, Ahmad AS, Yousuf S, Ansari MA, Khan MB, et al. Effect of saffron (*Crocus sativus*) on neurobehavioral and neurochemical changes in cerebral ischemia in rats. *Journal of medicinal food* 2006;9(2):246-53.
26. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al. A 22-week, multicenter, randomized, double-blind controlled trial of *Crocus sativus* in the treatment of mild-to-moderate Alzheimer's disease. *Psychopharmacology (Berl).* 2010;207(4):637-43. doi: 10.1007/s00213-009-1706-1
27. Karimi E, Oskoueian E, Hendra R, Jaafar HZE. Evaluation of *Crocus sativus* L. stigma phenolic and flavonoid compounds and its antioxidant activity. *Molecules.* 2010;15(9):6244-56. doi: 10.3390/molecules15096244
28. Farivar M, Hooshmandi Z, Setorki M, Amini S. Effect of *Elettaria cardamomum* essential oil and its main component (1,8-cineole) on brain damage caused by cerebral hypoperfusion by suppressing apoptosis and inflammation in rats. *Iran Red Crescent Med J.* 2020;22(12):e178. doi: 10.32592/ircmj.2020.22.12.178
29. Saini S, Choudhary M, Garg A. Investigation of nootropic potential of ethanol extract of *Elettaria cardamomum* Maton fruit (cardamom): a spice of India. *Clin Phytosci.* 2021;7:68. doi: 10.1186/s40816-021-00300-5
30. Shetty PK, Rani M, Rejeesh EP, Rao SN. A preclinical study of *Elettaria cardamomum* for its antianxiety activity in Wistar albino rats. *Asian J Med Sci.* 2023;14(11):79-83. doi: 10.3126/ajms.v14i11.55348
31. Zali H, Zamanian-Azodi M, Tavirani MR, Baghban AA-z. Protein drug targets of *Lavandula angustifolia* on treatment of rat Alzheimer's disease. *Iran J Pharm Res.* 2015;14(1):291-302. doi: 10.22037/ijpr.2015.1615
32. Kostadinović Veličkova S, Pljevljakušić D, Arsov E, Mitrev S, Dimovska D, Mihajlov Lj, et al. Chemical composition, antioxidant and antimicrobial effect of *Lavandula* essential oil used as a natural antioxidant for cold-pressed oils. *Proc. 11th CMAPSEEC (Medicinal & Aromatic Plants SE Europe).* 2022.
33. Li M, Cao X, Yan H, Wang M, Tashibolati A, Maiwulanjiang M. Integrating zebrafish model to screen active ingredients and network pharmacology methods to explore the mechanism of *Lavandula angustifolia* therapy for Alzheimer's disease. *ChemistrySelect.* 2022;7(28):e202201364. doi: 10.1002/slct.202201364

34. Kashani MS, Tavirani MR, Talaei SA, Salami M. Aqueous extract of *Lavandula angustifolia* improves the spatial performance of a rat model of Alzheimer's disease. *Neurosci Bull.* 2011;27(2):99-106. doi: 10.1007/s12264-011-1149-7
35. Dehbani Z, Komaki A, Etaee F, Shahidi S, Taheri M, Komaki S, et al. Effect of a hydro-alcoholic extract of *Melissa officinalis* on passive avoidance learning and memory. *J Herbmmed Pharmacol.* 2019;8(2):120-25. doi: 10.15171/jhp.2019.19
36. Bayat M, Azami Tameh A, Hossein Ghahremani M, Akbari M, Mehr SE, Khanavi M, et al. Neuroprotective properties of *Melissa officinalis* after hypoxic-ischemic injury both in vitro and in vivo. *DARU J Pharm Sci.* 2012;20:42. doi: 10.1186/2008-2231-20-42
37. Al Mamun A, Matsuzaki K, Islam R, Hossain S, Hossain ME, Katakura M, et al. Chronic administration of thymoquinone enhances adult hippocampal neurogenesis and improves memory in rats via regulating the BDNF signaling pathway. *Neurochem Res.* 2022;47(4):791-809. doi: 10.1007/s11064-021-03549-8
38. Cascella M, Bimonte S, Barbieri A, Del Vecchio V, Muzio MR, Vitale A, et al. Dissecting the potential roles of *Nigella sativa* and its constituent thymoquinone on the prevention and on the progression of Alzheimer's disease. *Front Aging Neurosci.* 2018;10:16. doi: 10.3389/fnagi.2018.00016
39. Hossain MS, Seddique AB, Sharmin S, Rashid MMO, Islam A, Hossain MM. *Nigella sativa* oil improves motor skill learning of albino mice: in vivo and in silico investigations. *Evid Based Complement Alternat Med.* 2023;2023:8498066. doi: 10.1155/2023/8498066
40. Mostafa NM, Mostafa AM, Ashour ML, Elhady SS. Neuroprotective effects of black pepper cold-pressed oil on scopolamine-induced oxidative stress and memory impairment in rats. *Antioxidants (Basel).* 2021;10(12):1993. doi: 10.3390/antiox10121993
41. Subedee L, Suresh RN, Jayanthi MK, Kalabharathi HL, Satish AM, Pushpa VH. Preventive role of Indian black pepper in animal models of Alzheimer's disease. *J Clin Diagn Res.* 2015;9(4):FF01-4. doi: 10.7860/JCDR/2015/8953.5767
42. Tu Y, Zhong Y, Du H, Luo W, Wen Y, Li Q, et al. Anticholinesterases and antioxidant alkaloids from *Piper nigrum* fruits. *Nat. Prod. Res.* 2016;30(17):1945-49. doi: 10.1080/14786419.2015.1089243
43. Teralı K, Özbeyli D, Yiğit-Hanoğlu D, Başer K H C, Şener G, Aykac A. A comprehensive assessment of the cholinergic-supporting and cognitive-enhancing effects of *Rosa damascena* Mill. (Damask Rose) essential oil on scopolamine-induced amnesic rats. *Brain Behav.* 2024;14(5):e3507. doi: 10.1002/brb3.3507
44. Beigom Hejaziyan L, Hosseini SM, Taravati A, Asadi M, Bakhshi M, Moshaei Nezhad P, et al. Effect of *Rosa damascena* extract on rat model Alzheimer's disease: a histopathological, behavioral, enzyme activities, and oxidative stress study. *Evid Based Complement Alternat Med.* 2023;2023:4926151. doi: 10.1155/2023/4926151
45. Esfandiary E, Karimipour M, Mardani M, Ghanadian M, Alaei H A, Mohammadnejad D, et al. Neuroprotective effects of *Rosa damascena* extract on learning and memory in a rat model of amyloid- β -induced Alzheimer's disease. *Adv Biomed Res.* 2015;4(1):131. doi: 10.4103/2277-9175.161512
46. Oboh G, Ademiluyi AO, Akinyemi AJ. Inhibition of acetylcholinesterase activities and some pro-oxidant induced lipid peroxidation in rat brain by two varieties of ginger (*Zingiber officinale*). *Exp Toxicol Pathol.* 2012;64(4):315-19. doi: 10.1016/j.etp.2010.09.004
47. Arcusa R, Villaño D, Marhuenda J, Cano M, Cerdà B, Zafrilla P. Potential role of ginger (*Zingiber officinale* Roscoe) in the prevention of neurodegenerative diseases. *Front Nutr.* 2022;9:809621. doi: 10.3389/fnut.2022.809621
48. Luo J-F, Dong Y, Chen J-Y, Lu J-H. The effect and underlying mechanisms of garlic extract against cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis of experimental animal studies. *J Ethnopharmacol.* 2021;280:114423. doi: 10.1016/j.jep.2021.114423

49. Sripanidkulchai B. Benefits of aged garlic extract on Alzheimer's disease: possible mechanisms of action. *Exp Ther Med*. 2020;19(2):1560–64. doi: 10.3892/etm.2019.8390
50. Tasnim S, Haque PS, Bari MS, Hossain MM, Islam SM, Shahriar M, et al. *Allium sativum* L. improves visual memory and attention in healthy human volunteers. *Evid Based Complement Alternat Med*. 2015;2015:103416. doi: 10.1155/2015/103416
51. Kumar S, Kumar S, Ram H. Anti-aggregation property of allicin by in vitro and molecular docking studies. *J Exp Neurosci*. 2019;13:1179069519866185. doi: 10.1177/1179069519866185
52. Gupta VB, Rao K. Anti-amyloidogenic activity of S-allyl-L-cysteine and its activity to destabilize Alzheimer's β -amyloid fibrils in vitro. *Neurosci Lett*. 2007;429(2-3):75-80. doi: 10.1016/j.neulet.2007.09.042
53. Gomaa AA, Makboul RM, Al-Mokhtar MA, Nicola MA. Polyphenol-rich *Boswellia serrata* gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3 β activity, oxidative stress and pro-inflammatory cytokines. *Biomed Pharmacother*. 2019;109:281-92. doi: 10.1016/j.biopha.2018.10.056
54. Ahmadian-Attari MM, Ahmadiani A, Kamalinejad M, Dargahi L, Shirzad M, Mosaddegh M. Treatment of Alzheimer's disease in Iranian traditional medicine. *Iran Red Crescent Med J*. 2015;17(1):e18256. doi: 10.5812/ircmj.18256
55. Yousefi O, Ghazi-Mirsaiid S, Azami P, Karimi G, Mani A, Niakan A, et al. Effect of a *Boswellia* and ginger mixture on the memory dysfunction of mild traumatic brain injury patients: a randomized, double-blind controlled trial. *Bull Emerg Trauma*. 2022;10(4):157-64. doi: 10.30476/beat.2022.97106.1400
56. Taghizadeh M, Maghaminejad F, Aghajani M, Rahmani M, Mahboubi M. The effect of tablet containing *Boswellia serrata* and *Melissa officinalis* extract on older adults' memory: a randomized controlled trial. *Arch Gerontol Geriatr*. 2018;75:146-50. doi: 10.1016/j.archger.2017.12.008
57. Saeri S, Hadjzadeh MA, Hosseini M, Hosseinian S, Arab Z. The effects of the combination of *Cyperus rotundus*, *Crocus sativus*, *Piper nigrum*, and *Boswellia serrata* on learning and memory deficit and oxidative damage in brain tissue of hypothyroid rats. *J Food Biochem*. 2020;44(9):e13391. doi: 10.1111/jfbc.13391
58. Ahmed HH, Mohamed EM, El-Dsoki SM. Evidences for the promising therapeutic potential of *Boswellia serrata* against Alzheimer's disease: pre-clinical study. *Int J Pharm Pharm Sci*. 2014;6(11):384-92.
59. Marefati N, Beheshti F, Vafae F, Barabadi M, Hosseini M. The effects of incense acetate on neuro-inflammation, brain-derived neurotrophic factor and memory impairment induced by lipopolysaccharide in rats. *Neurochem Res*. 2021;46(9):2473-84. doi: 10.1007/s11064-021-03381-3
60. Mohamed TM, Youssef MAM, Bakry AA, El-Keiy MM. Alzheimer's disease improved through the activity of mitochondrial chain complexes and their gene expression in rats by boswellic acid. *Metab Brain Dis*. 2021;36(2):255-64. doi: 10.1007/s11011-020-00639-7
61. Gomaa AA, Farghaly HA, Abdel-Wadood YA, Gomaa GA. Potential therapeutic effects of boswellic acids / *Boswellia serrata* extract in the prevention and therapy of type 2 diabetes and Alzheimer's disease. *Naunyn-Schmiedeberg's Arch Pharmacol*. 2021;394(11):2167–85. doi: 10.1007/s00210-021-02154-7
62. Sanaie S, Nikanfar S, Kalekhane ZY, Azizi-Zeinalhajlou A, Sadigh-Eteghad S, Araj-Khodaei M, et al. Saffron as a promising therapy for diabetes and Alzheimer's disease: mechanistic insights. *Metab Brain Dis*. 2023;38(1):137-62. doi: 10.1007/s11011-022-01108-8
63. Mollazadeh H, Emami SA, Hosseinzadeh H. Razi's *Al-Hawi* and saffron (*Crocus sativus*): a review. *Iran J Basic Med Sci*. 2015;18(12):1153-66.

64. D'Onofrio G, Nabavi SM, Sancarolo D, Greco A, Pieretti S. *Crocus sativus* L. (saffron) in Alzheimer's disease treatment: bioactive effects on cognitive impairment. *Curr Neuropharmacol*. 2021;19(9):1606-21. doi: 10.2174/1570159X19666210419121827
65. Zandi N, Pazoki B, Roudsari NM, Lashgari N-A, Jamshidi V, Momtaz S, et al. Prospects of saffron and its derivatives in Alzheimer's disease. *Arch Iran Med*. 2021;24(3):233-52.
66. Bian Y, Zhao C, Lee SM-Y. Neuroprotective potency of saffron against neuropsychiatric diseases, neurodegenerative diseases, and other brain disorders: from bench to bedside. *Front Pharmacol*. 2020;11:579052. doi: 10.3389/fphar.2020.579052
67. Geromichalos GD, Lamari FN, Papandreou MA, Trafalis DT, Margarity M, Papageorgiou A, et al. Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. *J Agric Food Chem*. 2012;60(24):6131-8. doi: 10.1021/jf300889b
68. Tomar D, Taumar D, Jain P, Goel K, Jindal A. Crocin as neuroprotective agonist in oxidative damage and cognitive dysfunction induced by aluminium chloride and colchicine in rodents. *Curr Res Pharm Sci*. 2023;3:52-69.
69. Hadipour M, Kaka G, Bahrami F, Meftahi GH, Pirzad Jahromi G, Mohammadi A, et al. Crocin improved amyloid beta-induced long-term potentiation and memory deficits in the hippocampal CA1 neurons in freely moving rats. *Synapse*. 2018;72(5):e22026. doi: 10.1002/syn.22026
70. Behravanfar N, Abnous K, Razavi BM, Hosseinzadeh H. Effects of crocin on spatial memory impairment induced by hyoscine and its effects on BDNF, CREB, and p-CREB protein and mRNA levels in rat hippocampus. *Jundishapur J Nat Pharm Prod*. 2017;12(3 Suppl):e12345.
71. Kuchta K, Aritake K, Urade Y, Nguyen H T, Yuan C-S, Sasaki Y, et al. Preventing dementia using saffron, the Kampo medicine, Kamiuntanto, and their combination, Kamiuntantokabankoka. *Front Pharmacol*. 2022;12:779821. doi: 10.3389/fphar.2021.779821
72. Asgary S, Yazdiniapour Z. Saffron and depression. *Bioact Compd Health Dis*. 2021;4(5):90-2. doi: 10.31989/bchd.v4i5.820
73. Tashakori-Sabzevar F, Hosseinzadeh H, Sadat Motamedshariaty V, Reza Movassaghi A, Ahmad Mohajeri S. Crocetin attenuates spatial learning dysfunction and hippocampal injury in a model of vascular dementia. *Curr Neurovasc Res*. 2013;10(4):325-34. doi: 10.2174/1567202611310040009
74. Kuriakose G, Sinu PA, Shivanna KR. Domestication of cardamom (*Elettaria cardamomum*) in Western Ghats, India: divergence in productive traits and a shift in major pollinators. *Ann Bot*. 2009;103(5):727-33. doi: 10.1093/aob/mcp024
75. Pavarino M, Marengo A, Cagliero C, Bicchi C, Rubiolo P, Sgorbini B. *Elettaria cardamomum* (L.) Maton essential oil: an interesting source of bioactive specialized metabolites as inhibitors of acetylcholinesterase and butyrylcholinesterase. *Plants (Basel)*. 2023;12(19):3463. doi: 10.3390/plants12193463
76. Daneshi-Maskooni M, Keshavarz SA, Mansouri S, Qorbani M, Alavian SM, Badri-Fariman M, et al. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraoxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. *Trials*. 2017;18:1-9. doi: 10.1186/s13063-017-1888-2
77. Carrasco A, Martinez-Gutierrez R, Tomas V, Tudela J. *Lavandula angustifolia* and *Lavandula latifolia* essential oils from Spain: aromatic profile and bioactivities. *Planta Med*. 2016;82(1-2):163-70. doi: 10.1055/s-0041-108134
78. Omurtag Ö PS, Biltekin SN, İduğ T, Macit Ç, Ayran İ, Çelik SA, et al. Chemical composition and in vitro mutagenic, antioxidant and anti-inflammatory activities of *Lavandula angustifolia* Mill. essential oil from Turkey. *J Res Pharm*. 2022;26(4):781-89. doi: 10.29228/jrp.175
79. Ferreira A, Proença C, Serralheiro MLM, Araújo MEM. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. *J Ethnopharmacol*. 2006;108(1):31-7. doi: 10.1016/j.jep.2006.04.010

80. Dolatkhah N, Rajabi M, Rahbar M, Shakouri K, Mirzazadeh Y, Janbaz Alamdary S, et al. Investigating the therapeutic effects of *Melissa officinalis* on clinical and electro-diagnostic findings of patients with type 2 diabetes. *Biomed Res Bull.* 2024;2(4):162-71. doi: 10.34172/biomedrb.2024.22
81. Soodi M, Dashti A, Hajimehdipoor H, Akbari S, Ataei N. *Melissa officinalis* acidic fraction protects cultured cerebellar granule neurons against beta amyloid-induced apoptosis and oxidative stress. *Cell J.* 2017;18(4):556-64. doi: 10.22074/cellj.2016.4722
82. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. *Curr Pharm Des.* 2006;12(35):4613-23. doi: 10.2174/138161206779010090
83. Kennedy DO, Scholey AB, Tildesley N, Perry E, Wesnes K. Modulation of mood and cognitive performance following acute administration of *Melissa officinalis* (lemon balm). *Pharmacol Biochem Behav.* 2002;72(4):953-64. doi: 10.1016/S0091-3057(02)00990-7
84. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. *Melissa officinalis* extract in the treatment of patients with mild to moderate Alzheimer's disease: a double-blind, randomised, placebo-controlled trial. *J Neurol Neurosurg Psychiatry.* 2003;74(7):863-6. doi: 10.1136/jnnp.74.7.863
85. Gholamnezhad Z, Havakhah S, Boskabady MH. Preclinical and clinical effects of *Nigella sativa* and its constituent, thymoquinone: a review. *J Ethnopharmacol.* 2016;190:372-86. doi: 10.1016/j.jep.2016.06.055
86. Hannan MA, Rahman MA, Sohag AAM, Uddin MJ, Dash R, Sikder MH, et al. Black cumin (*Nigella sativa* L.): a comprehensive review on phytochemistry, health benefits, molecular pharmacology, and safety. *Nutrients.* 2021;13(6):1782. doi: 10.3390/nu13061782
87. Bin Sayeed MS, Asaduzzaman M, Morshed H, Hossain MM, Kadir MF, Rahman MR. The effect of *Nigella sativa* Linn. seed on memory, attention and cognition in healthy human volunteers. *J Ethnopharmacol.* 2013;148(3):780-6. doi: 10.1016/j.jep.2013.05.004
88. Bin Sayeed MS, Shams T, Fahim Hossain S, Rahman MR, Mostofa A, Fahim Kadir M, et al. *Nigella sativa* L. seeds modulate mood, anxiety and cognition in healthy adolescent males. *J Ethnopharmacol.* 2014;152(1):156-62. doi: 10.1016/j.jep.2013.12.050
89. Salehi B, Zakaria ZA, Gyawali R, Ibrahim SA, Rajkovic J, Shinwari ZK, et al. *Piper* species: a comprehensive review on their phytochemistry, biological activities and applications. *Molecules.* 2019;24(7):1364. doi: 10.3390/molecules24071364
90. Dabaghian F, Azadi A, Zarshenas MM. Design, reformulation, and standardization of a traditional-based memory enhancer herbal preparation originated from Persian medicine. *J Med Plants.* 2022;21(82):93-110. doi: 10.52547/jmp.21.82.93
91. Tajadini H, Saifadini R, Chooani R, Mehrabani M, Kamalinejad M, Haghdoost AA. Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: a 12-week randomized double-blind placebo-controlled clinical trial. *Complement Ther Med.* 2015;23(6):767-72. doi: 10.1016/j.ctim.2015.09.009
92. Lindheimer JB, Loy BD, O'Connor PJ. Short-term effects of black pepper (*Piper nigrum*) and rosemary (*Rosmarinus officinalis* and *Rosmarinus eriocalyx*) on sustained attention and on energy and fatigue mood states in young adults with low energy. *J Med Food.* 2013;16(8):765-71. doi: 10.1089/jmf.2012.0216
93. Babaei A, Tabaei-Aghdaei SR, Khosh-Khui M, Omidbaigi R, Naghavi MR, Esselink GD, et al. Microsatellite analysis of Damask rose (*Rosa damascena* Mill.) accessions from various regions in Iran reveals multiple genotypes. *BMC Plant Biol.* 2007;7:12. doi: 10.1186/1471-2229-7-12
94. Nayebi N, Khalili N, Kamalinejad M, Emtiazy M. A systematic review of the efficacy and safety of *Rosa damascena* Mill. with an overview on its phytopharmacological properties. *Complement Ther Med.* 2017;34:129-40. doi: 10.1016/j.ctim.2017.03.008
95. Boskabady MH, Shafei MN, Saberi Z, Amini S. Pharmacological effects of *Rosa damascena*. *Iran J Basic Med Sci.* 2011;14(4):295-307.

96. Esfandiary E, Abdolali Z, Omranifard V, Ghanadian M, Bagherian-Sararoud R, Karimipour M, et al. Novel effects of *Rosa damascena* extract on patients with neurocognitive disorder and depression: a clinical trial study. *Int J Prev Med*. 2018;9:45. doi: 10.4103/ijpvm.IJPVM_233_17
97. Sulieman AME, Ibrahim SM, Alshammari M, Abdulaziz F, Idriss H, Alanazi NAH, et al. *Zingiber officinale* uncovered: integrating experimental and computational approaches to antibacterial and phytochemical profiling. *Pharmaceuticals (Basel)*. 2024;17(11):1605. doi: 10.3390/ph17111605
98. Kim C-Y, Seo Y, Lee C, Park GH, Jang J-H. Neuroprotective effect and molecular mechanism of [6]-gingerol against scopolamine-induced amnesia in C57BL/6 mice. *Evid Based Complement Alternat Med*. 2018;2018:8941564. doi: 10.1155/2018/8941564
99. Cuya T, Baptista L, Celmar Costa França T. A molecular dynamics study of components of the ginger (*Zingiber officinale*) extract inside human acetylcholinesterase: implications for Alzheimer disease. *J Biomol Struct Dyn*. 2018;36(14):3843-55. doi: 10.1080/07391102.2017.1377631
100. Farombi EO, Abolaji AO, Adetuyi BO, Awosanya O, Fabusoro M. Neuroprotective role of 6-gingerol-rich fraction of *Zingiber officinale* (ginger) against acrylonitrile-induced neurotoxicity in male Wistar rats. *J Basic Clin Physiol Pharmacol*. 2019;30(3):20180114. doi: 10.1515/jbcpp-2018-0114
101. Panahishokouh M, Noroozian M, Mohammadian F, Khanavi M, Mirimoghaddam M, Savar SM, et al. Evaluation of the effectiveness of an herbal formulation of *Boswellia sacra* Flueck. in improving cognitive and behavioral symptoms in patients with cognitive impairment and Alzheimer's disease. *J Res Pharm Pract*. 2022;11(3):91-8. doi: 10.4103/jrpp.jrpp_73_22
102. Sedighi B, Pardakhty A, Kamali H, Shafiee K, Hasani BN. Effect of *Boswellia papyrifera* on cognitive impairment in multiple sclerosis. *Iran J Neurol*. 2014;13(3):149.
103. Abbaszadeh-Mashkani S, Hoque SS, Banafshe HR, Ghaderi A. The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment. *Phytother Res*. 2021;35(3):1486-94.
104. Moazen-Zadeh E, Abbasi SH, Safi-Aghdam H, Shahmansouri N, Arjmandi-Beglar A, Hajhosseinn Talasaz A, et al. Effects of saffron on cognition, anxiety, and depression in patients undergoing coronary artery bypass grafting: a randomized double-blind placebo-controlled trial. *J Altern Complement Med*. 2018;24(4):361-8. doi: 10.1089/acm.2017.0173
105. Tsolaki M, Karathanasi E, Lazarou I, Dovas K, Verykoui E, Karacostas A, et al. Efficacy and safety of *Crocus sativus* L. in patients with mild cognitive impairment: one-year single-blind randomized, parallel-groups clinical trial. *J Alzheimers Dis*. 2016;54(1):129-33. doi: 10.3233/jad-160304
106. Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized, placebo-controlled trial. *J Clin Pharm Ther*. 2010;35(5):581-8. doi: 10.1111/j.1365-2710.2009.01133.x
107. Wightman E, Khan J, Smith E, Rolfe V, Smith D, Young G, et al. Chronic supplementation of a multi-ingredient herbal supplement increases speed of cognitive task performance alongside changes in the urinary metabolism of dopamine and the gut microbiome in cognitively intact older adults experiencing subjective memory decline: a randomized, placebo-controlled, parallel-groups investigation. *Front Nutr*. 2023;10:1257516. doi: 10.3389/fnut.2023.1257516
108. Moss M, Cook J, Wesnes K, Duckett P. Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. *Int J Neurosci*. 2003;113(1):15-38. doi: 10.1080/00207450390161903
109. Jimbo D, Kimura Y, Taniguchi M, Inoue M, Urakami K. Effect of aromatherapy on patients with Alzheimer's disease. *Psychogeriatrics*. 2009;9(4):173-9. doi: 10.1111/j.1479-8301.2009.00299.x
110. Dehghan N, Azizzadeh Forouzi M, Etminan A, Roy C, Dehghan M. The effects of lavender, rosemary, and orange essential oils on memory problems and medication adherence among patients undergoing hemodialysis: a parallel randomized controlled trial. *Explore (NY)*. 2022;18(5):559-66. doi: 10.1016/j.explore.2021.10.004

111. Can S, Yildirim Usta Y, Yildiz S, Tayfun K. The effect of lavender and rosemary aromatherapy application on cognitive functions, anxiety, and sleep quality in the elderly with diabetes. *Explore (NY)*. 2024;20(6):103033. doi: 10.1016/j.explore.2024.103033
112. Mohammad Rezaie S, Shahabinejad M, Loripoor M, Sayadi AR. The effect of aromatherapy with lavender essential oil on the working memory of women with multiple sclerosis. *J Med Life*. 2021;14(6):776-81. doi: 10.25122/jml-2020-0115
113. Afghan R, Heysieattalab S, Zangbar HS, Ebrahimi-Kalan A, Jafari-Koshki T, Samadzadehaghdam N. Lavender essential oil inhalation improves attentional shifting and accuracy: evidence from dynamic changes of cognitive flexibility and power spectral density of electroencephalogram signals. *J Med Signals Sens*. 2024;14:12. doi: 10.4103/jmss.jmss_57_23
114. Malloggi E, Menicucci D, Cesari V, Frumento S, Gemignani A, Bertoli A. Lavender aromatherapy: a systematic review from essential oil quality and administration methods to cognitive enhancing effects. *Appl Psychol Health Well-Being*. 2022;14(2):663-90. doi: 10.1111/aphw.12310
115. Noguchi-Shinohara M, Hamaguchi T, Sakai K, Komatsu J, Iwasa K, Horimoto M, et al. Effects of *Melissa officinalis* extract containing rosmarinic acid on cognition in older adults without dementia: a randomized controlled trial. *J Alzheimers Dis*. 2023;91(2):805-14. doi: 10.3233/jad-220953
116. Noguchi-Shinohara M, Ono K, Hamaguchi T, Nagai T, Kobayashi S, Komatsu J, et al. Safety and efficacy of *Melissa officinalis* extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. *Sci Rep*. 2020;10(1):18627. doi: 10.1038/s41598-020-73729-2
117. Kennedy DO, Wake G, Savelev S, Tildesley NT, Perry EK, Wesnes KA, et al. Modulation of mood and cognitive performance following acute administration of single doses of *Melissa officinalis* (lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. *Neuropsychopharmacology*. 2003;28(10):1871-81. doi: 10.1038/sj.npp.1300230
118. Perry NSL, Menzies R, Hodgson F, Wedgewood P, Howes MR, Brooker HJ, et al. A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary, and *Melissa*, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age. *Phytomedicine*. 2018;39:42-8. doi: 10.1016/j.phymed.2017.08.015
119. Saenghong N, Wattanathorn J, Muchimapura S, Tongun T, Piyavhatkul N, Banchonglikitkul C, et al. *Zingiber officinale* improves cognitive function of middle-aged healthy women. *Evid Based Complement Alternat Med*. 2012;2012:383062.
120. Wang W, Huang C, Ku J. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. *J Neurosci Res*. 2006;12(27):3521-33.
121. Kearns P. Gut-brain axis and neuroinflammation: the role of gut permeability and the kynurenine pathway in neurological disorders. *Cell Mol Neurobiol*. 2024;44(1):64.



Figure 1. Captured images of selected medicinal plants.




Figure 2. Summarized mechanisms contributing to the neuroprotective effects of TPM medicinal plants. Note: Amyloid-β: Amyloid beta, BDNF: Brain Derived Neurotrophic Factor, Cas 3 & 9: Caspase-3 & 9, CREB: cAMP-response element binding protein, GSK-3β: Glycogen synthase kinase-3 beta.